ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO279

Association between Urinary Full-Length Megalin and Serum Vitamin D Metabolites in CKD

Session Information

Category: Mineral Disease

  • 1202 Mineral Disease: Vitamin D, PTH, FGF-23

Authors

  • Toi, Norikazu, Osaka City University Graduate School of Medicine, Osaka, Japan
  • Yamada, Shinsuke, a. Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
  • Ishimura, Eiji, Meijibashi Hospital, Osaka, Japan
  • Nakatani, Ayumi, Osaka City University Graduate School of Medicine, Osaka, Japan
  • Nakatani, Shinya, Osaka City University Graduate School of Medicine, Osaka, Japan
  • Hirayama, Yoshiaki, Denka-seiken co., ltd., Gosen-shi, Japan
  • Tsugawa, Naoko, Osaka Shoin Women''s University, Higashi-osaka, Japan
  • Saito, Akihiko, Niigata University, Niigata, Japan
  • Inaba, Masaaki, Osaka City University Graduate School of Medicine, Osaka, Japan
Background

25-hydroxyvitamin D (25D) bound to vitamin D binding protein is reabsorbed by megalin, which is a membrane receptor highly expressed on proximal tubular epithelial cells. Increase in urinary megalin excretion due to tubular injury may affect vitamin D metabolism in chronic kidney disease (CKD) patients. The aim of the present study was to investigate whether increase in urinary excretion of megalin may have harmful effects on vitamin D metabolism in CKD patients.

Methods

One hundred fifty three CKD patients with eGFR less than 60 mL/min/1.73m2 (101 males and 53 females, 64.7 ± 14.6 years) were recruited in this cross-sectional study. Urinary full-length megalin (C-megalin) and serum vitamin D metabolites (25D, 1α,25-dihydroxyvitamin D (1,25D), 24,25-dihydroxyvitamin D (24,25D) were measured.

Results

The mean levels of eGFR, serum levels of 25D, and urinary levels of C-megalin were 29.0 ± 15.8 mL/min/1.73m2, 15.1 ± 6.2 ng/mL and 0.9 ± 1.1 pmol/gCr, respectively. In a simple regression analysis, 25D exhibited significant and negative correlation with urinary C-megalin (ρ = - 0.310, p = 0.0002), and urinary C-megalin had a significant and positive correlation with urinary protein (ρ = 0.603, p <0.0001), although both 25D and urinary C-megalin was not significantly correlated with eGFR. In a multiple regression analysis adjusted by age, gender, BMI, presence of diabetes, serum albumin, eGFR, serum PTH, serum FGF-23, and urinary C-megalin, urinary C-megalin was associated significantly with 25D in a negative manner (β = - 0.302, p = 0.0027). Furthermore, both 1,25D (β = 0.227, p = 0.0013) and 24,25D (β = 0.482, p <0.0001) were positively associated with 25D. The ratio of 1,25D/24,25D, which is a putative indicator of 1α-hydroxylase activity, was significantly, positively affected by urinary C-megalin independently to other clinical confounders.

Conclusion

This study demonstrated that serum 25D decreases with an increase in urinary C-megalin, and that serum 1,25D and 24,25D decrease with a decrease in 25D in CKD patients. Thus, decreased 25D induced by increased urinary C-megalin, which is a representative of tubular injury, affects decrease in 1,25D, suggesting the clinical importance of renal tubular dysfunction in vitamin D metabolism in CKD patients.